ANSES Reshuffles Human Nutrition Expert Committee: Regulatory Shifts Anticipated
France's ANSES has updated its Human Nutrition Specialised Expert Committee composition, signalling potential shifts in future supplement regulation and safety assessments. Manufacturers should anticipate revised guidance and ingredient evaluations influencing product development and market access.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Paris, France — 31 August 2026
The French Agency for Food, Environmental and Occupational Health & Safety (ANSES) has formally announced Decision N°2026-099, updating the composition of its Specialised Expert Committee (CES) on Human Nutrition. This change, signed on 06 July 2026 and published on 31 August 2026, reorganises the scientific expertise responsible for evaluating nutrition-related health risks and benefits within France. The committee's assessments form the basis for national regulatory recommendations and influence European Food Safety Authority (EFSA) opinions, making these appointments critical for the supplement sector.
The CES Human Nutrition is instrumental in evaluating the safety and efficacy of ingredients used in food supplements, novel foods, and fortified products. Its mandate includes risk assessment related to dietary exposure, nutritional requirements, and potential adverse effects of specific compounds. The revised panel composition could introduce new scientific perspectives on acceptable daily intakes (ADIs), maximum levels for vitamins and minerals, and the substantiation of health claims, particularly for emerging ingredients or complex botanical extracts.
Manufacturers and brand owners operating within or seeking to enter the French market must closely monitor the committee's subsequent output. Changes in scientific consensus or risk perception regarding certain nutrients or ingredients could necessitate product reformulation, updated labelling, or even market withdrawal for non-compliant products. The agency's assessments often drive the need for new toxicological data or clinical substantiation, raising compliance costs and extending product development cycles.
What this means for France
French supplement manufacturers must proactively audit their product portfolios against potential shifts in ANSES's scientific opinions, especially for high-dose ingredients or those with limited long-term safety data. Reformulation windows could tighten significantly, requiring accelerated R&D and supply chain adjustments. Brand owners should prepare for potentially stricter enforcement of health claim substantiation, impacting marketing strategies and requiring additional investment in clinical trials. Procurement leads need to assess supplier readiness for updated raw material specifications and documentation requirements to mitigate supply continuity risks and avoid stock write-offs due to regulatory non-compliance. This recalibration of expert opinion may also create market entry barriers for non-EU manufacturers if national regulatory divergence from EFSA opinions increases.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.